Pharmaceutical Consulting | India & Global

Project Planning & Feasibility for Pharma, Biotech & Manufacturing

Start Your Feasibility Study

CDSCO · Schedule M · WHO-GMP Experts

India & 20+ Global Markets

Quick Answer

A pharmaceutical project feasibility study checks whether your plant setup idea is technically sound, financially realistic, and regulatory-ready — before you spend a single rupee on construction. It covers site selection, cost estimation (CapEx & OpEx), Schedule M and CDSCO compliance for India, WHO-GMP or US FDA alignment for exports, risk assessment, and a clear project roadmap.

Overview

What Is Pharma Project Planning & Feasibility?

Every year, dozens of pharma plant projects in India stall or fail — not because of poor execution, but because of poor planning. A promoter buys land and begins construction, only to discover later that the site doesn’t meet HVAC or water quality norms, or the regulatory approval pathway will take two years longer than expected.

A proper feasibility study prevents these expensive surprises. It gives you a clear, evidence-based answer on whether to proceed, how to proceed, and what it will truly cost — in time, money, and effort.

Whether you are setting up a new solid dosage facility in Gujarat, an injectable plant in Himachal Pradesh, or an API unit targeting the US market, project planning and feasibility is the most important step you will take.

Who needs this service? Pharma entrepreneurs, biotech founders, manufacturing investors, CMO operators, exporters planning WHO-GMP or US FDA approvals, and existing manufacturers looking to expand capacity or add dosage forms.

Why It Matters

Why Project Feasibility Is Not Optional

Skipping feasibility is the single biggest reason pharma projects run over budget, miss timelines, and fail regulatory audits.

Cost Overruns Are Common

Industry data shows that up to 40% of pharma projects exceed their original budget. Most overruns happen when CapEx is estimated without proper site assessment, utility planning, or equipment sourcing analysis. A feasibility study fixes this upfront.

Delays Kill ROI

A 12-month delay in getting CDSCO licensing or Schedule M GMP certification can erode your projected ROI by 15–25%. Planning the regulatory pathway from day one — including state drug authority approvals — is what keeps timelines on track.

Wrong Site = Rebuild Costs

Site selection is often underestimated. Poor water quality, unstable power supply, or zoning non-compliance can require expensive retrofits. Feasibility-level site due diligence prevents costly corrections after construction begins.

Banks & Investors Demand It

A detailed project report (DPR) with feasibility data is mandatory for bank loans, PE investment, or government scheme applications (PLI, MSME credit). Without it, funding conversations stall before they begin.

Regulatory Surprises Are Costly

Discovering mid-construction that your clean room classification doesn't meet Schedule M requirements — or that you need an EIA clearance — adds months and crores to your project. Regulatory pre-assessment eliminates this risk.

Market Fit Must Be Validated

Is there demand for the products you plan to manufacture? Are input raw materials reliably sourced? Can your pricing compete domestically and in export markets? Market feasibility answers these before capital is committed.

Scope of Service

What Does a Complete Feasibility Study Include?

A comprehensive pharma project feasibility study covers seven core dimensions. Each one protects a different aspect of your investment.

Market Feasibility

Analysis of product demand, competitor landscape, import-export data, pricing benchmarks, and customer segments. Validates whether there is a profitable market for your planned output — domestic or export.

Technical Feasibility

Evaluation of manufacturing technology, process design, equipment selection, HVAC and cleanroom requirements, utility needs (water, power, compressed air), and raw material sourcing. Checks if the project can technically be built and operated.

Site Selection & Due Diligence

Multi-location comparison covering land availability, connectivity, water source quality, power reliability, proximity to suppliers, state government incentives, zoning regulations, and environmental clearance requirements.

Financial Estimation (CapEx & OpEx)

Detailed capital expenditure (construction, equipment, utilities, validation, documentation) and operating cost estimates (manpower, materials, overheads). Includes break-even analysis, payback period, and IRR/NPV projections.

Regulatory Planning

Complete regulatory pathway mapping — CDSCO manufacturing license, Schedule M GMP compliance, state drug authority approvals, pollution control, factory licensing, and (if applicable) WHO-GMP, US FDA, or EU GMP readiness assessment.

Risk Assessment

Identification and scoring of technical, regulatory, financial, supply chain, and operational risks. Each risk is mapped with probability, impact, and a specific mitigation plan — so you are never caught off guard.

Scalability & Expansion Planning

Future-proofing your facility design. Can you add production lines, expand capacity, or introduce new dosage forms without rebuilding? Scalability planning is built into the layout and design strategy from day one.

Project Timeline & Milestones

A realistic, phase-wise project timeline from land finalization to commercial production. Includes critical path analysis, vendor selection milestones, approval timelines, and validation schedules — typically ranging from 12 to 24 months.

Regulatory Planning

Regulatory Considerations: India vs. Global Markets

The regulatory pathway varies significantly depending on your target market. Getting this right at the feasibility stage saves enormous time and money later

Core Facility Engineering Areas

Master Site Planning & Plant Layout Greenfield site selection, facility master planning, building orientation, and unidirectional flow design for materials, personnel, and waste that meets CDSCO Schedule M and WHO-GMP requirements.
Cleanroom Design & Classification ISO 5 (Grade A) to ISO 8 (Grade D) cleanrooms for sterile injectables, oral solids, biologics, APIs, and medical devices. Includes airlock design, gowning areas, and pressure differential mapping.nnel, and waste that meets CDSCO Schedule M and WHO-GMP requirements.
HVAC System Design Validated heating, ventilation, and air conditioning systems with HEPA/ULPA filtration, variable air volume (VAV) control, temperature & humidity regulation, and air change rates per ISO 14644 and Schedule M.
Utilities & Process Engineering Purified Water (PW), Water for Injection (WFI), Clean Steam, compressed air, nitrogen, and process gases. System design, loop layout, and qualification protocols.
Electrical & Instrumentation Engineering ower distribution, area classification for hazardous zones, building management systems (BMS), and 21 CFR Part 11-compliant automation and SCADA design.
Equipment Layout & Process Flow Design Pharmaceutical-grade equipment placement, maintenance access planning, cross-contamination prevention, and process flow optimisation for every dosage form.
Commissioning, Qualification & Validation (CQV) Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) documentation and execution.
BIM & 3D Facility ModellingBuilding Information Modelling (BIM) for clash detection, stakeholder reviews, and construction coordination, reducing costly on-site changes by up to 40%.

Facility Types We Serve

💊 Oral Solid Dosage (OSD) — tablets, capsules, granules

💉 Sterile Injectables — vials, ampoules, prefilled syringes

🧬 Biologics & Biosimilars — monoclonal antibodies, vaccines

⚗️ Active Pharmaceutical Ingredients (API)

🩺 Medical Devices — Class A, B, C, D (CDSCO)

🔬 Biotech & R&D Laboratories

🌿 Ayurvedic & Herbal Manufacturing

🏭 Contract Manufacturing Organisations (CMO)

India-Specific Note: For medical device manufacturers, our facility designs address CDSCO MD-5 and MD-9 licensing requirements, ISO 13485 quality system integration, and cleanroom standards for Class C and Class D devices under the Medical Devices Rules, 2017.

Cleanroom & HVAC

Cleanroom Design & HVAC Planning — The Technical Core

Cleanroom Classification — What Grade Do You Need?

The required cleanroom grade depends entirely on your product type and the specific manufacturing step. Here is a practical guide:

EU GMP Grade	ISO Class	Typical Use	Air Changes/hr
Grade A	ISO 5	Aseptic filling, stopper handling, open product exposure	Unidirectional (0.45 m/s)
Grade B	ISO 7	Background zone for Grade A; sterile gowning	20–40+
Grade C	ISO 8	Less critical sterile steps; solution preparation	20–40
Grade D	ISO 8+	Non-sterile: granulation, tabletting, packaging	6–20

* CDSCO Schedule M and WHO–GMP use the same EU GMP Grade A–D classification system. US FDA uses ISO 5 = Class 100, ISO 7 = Class 10,000 etc. (Federal Standard 209E, now superseded by ISO 14644).

HVAC System Design — What We Engineer

A pharma HVAC system is fundamentally different from a regular air conditioning system. It must simultaneously control:

Airborne particle count — via HEPA (99.97% for ≥0.3 μm) or ULPA filtration, mandatory for Grade A/B cleanrooms.
Pressure differentials — minimum 10–15 Pa positive pressure between adjacent rooms to prevent cross-contamination.
Temperature & humidity — typically 18–22°C, 40–60% RH for most APIs; tighter for hygroscopic or thermo-sensitive products.
Air change rates (ACH) — validated per product risk, not just prescribed numbers. Note: air change rate alone is not a reliable indicator of cleanroom performance (per ISO 14644-16).
Energy efficiency — pharma HVAC can consume 50–80% of facility energy. We design VAV systems, heat recovery, and zoned AHUs to reduce OPEX without compromising compliance.

Schedule M HVAC Requirement: Under revised CDSCO Schedule M, all critical HVAC systems must be qualified (IQ/OQ/PQ), continuously monitored, and backed by validated air handling unit maintenance procedures. BMS integration with real-time alarms is now expected for new facility approvals.

Regulatory Compliance

Regulatory Framework — India vs. Global Standards

Building a pharma facility in India but also want US FDA or EU approvals? Here is exactly how the standards overlap — and where they differ.

Requirement Area	India (CDSCO / Schedule M) IN	US FDA (21 CFR Part 211) US	EU GMP / WHO-GMP EU
Premises & Layout	Schedule M Part I: Adequate space, unidirectional flow, pest control, GMP construction materials Mandatory	21 CFR 211.42: Adequate size & construction; separate areas for different operations Required	EU GMP Chapter 3 / WHO-GMP Chapter 12: Size, design, layout to minimise contamination risk Required
Cleanrooms & Air Quality	ISO 14644 classification; Grade A–D; HEPA; particle monitoring Mandatory	21 CFR 211.42(c): Environmental controls; FDA aseptic guidance Required	EU GMP Annex 1: Contamination Control Strategy (CCS); Grade A–D Required
HVAC Qualification	IQ, OQ, PQ of AHUs; monitoring; BMS integration Mandatory	HVAC validation; periodic requalification; 21 CFR 211.68 Required	EU Annex 15 validation; Annex 11; risk-based approach Required
Water Systems	PW & WFI systems; loop design; monitoring; sanitisation Mandatory	21 CFR 211.48; USP PW & WFI; periodic testing Required	WHO TRS 929; PW & WFI specs; continuous monitoring Required
Documentation & Data Integrity	Electronic records, ALCOA+, audit trails Now Mandatory	21 CFR Part 11: electronic records & signatures Required	EU GMP Annex 11; data integrity guidance Required

Key 2026 Update: India’s revised Schedule M (phased implementation 2023–2025) now requires all new pharmaceutical manufacturing facilities to have a documented Quality Risk Management programme, annual Product Quality Reviews, and validated computerised systems — requirements that previously applied only to WHO-GMP export sites. This effectively raises the baseline for all CDSCO-licensed Indian manufacturers.

Our Process

Our Step-by-Step Facility Design & Engineering Process

Every project follows a structured, stage-gated process. No surprises, no scope creep, and full regulatory traceability at every stage.

Product & Regulatory Scoping

We start by understanding your product portfolio, target markets, and applicable regulations (CDSCO, US FDA, EU GMP). We define cleanroom grades, utility requirements, and a regulatory strategy before any drawing begins.

Concept Design & Feasibility

We create concept block flow diagrams, area zoning plans, preliminary equipment lists, and a site feasibility assessment. This stage produces the User Requirement Specification (URS) — the regulatory backbone of your project.

Basic Design (FEED)

Front-End Engineering Design covers plot plans, floor layouts, HVAC zoning, utility flow diagrams, P&IDs, electrical area classification, and preliminary capital cost estimates. FEED deliverables support CDSCO licence applications.

Detailed Engineering Design

Full construction drawings (civil, structural, MEP), equipment layouts with maintenance access, detailed HVAC design with air balance calculations, utilities sizing, and BIM 3D modelling for clash-free construction.

Construction Oversight & Procurement Support

We review contractor submittals, oversee GMP construction compliance, support vendor qualification for critical equipment, and manage design changes with full documentation to avoid qualification gaps.

Commissioning, Qualification & Validation

We execute DQ, FAT/SAT, IQ, OQ, PQ for all critical systems — HVAC, water, clean utilities, and process equipment. All validation protocols and reports are prepared to support regulatory submissions.

Regulatory Submission Support & Inspection Readiness

We prepare your Site Master File (SMF), HVAC qualification dossier, and plant design documentation package for CDSCO Drug Manufacturing Licence (Form 25/28), WHO-GMP certification, or US FDA inspection preparation.

Documentation

Facility Design Documentation — What You Receive

Regulatory inspections are won and lost on documentation. Every design decision must be traceable. Here is exactly what our facility design package delivers:

Pharmaceutical Manufacturing

Design Qualification (DQ) Report

Site Master File (SMF) Inputs

Equipment Layout & GA Drawings

HVAC Design Report & Air Balance

P&ID Drawings (Utilities & Process)

Electrical Area Classification Drawings

Water System Loop Design & DQ

IQ / OQ / PQ Protocol Templates

Cleanroom Classification Report (ISO 14644)

Regulatory Submission Package (CDSCO Form 25/28)

Data Integrity & Computerised System URS

All documents are formatted for electronic document management systems (EDMS), with version control, metadata tagging, and digital signature compatibility per 21 CFR Part 11 and revised Schedule M requirements.

Common Mistakes to Avoid

7 Facility Design Mistakes That Trigger Regulatory Failures

These are the mistakes we see again and again — in Indian pharma facilities and globally. Each one can delay your approval, trigger a warning letter, or force expensive retrofits.

Designing Rooms Before Defining Process Flow

The most common mistake: drawing rooms and corridors before mapping product, material, and personnel flow. This almost always creates cross-contamination risks or inefficient layouts that regulators flag immediately.

Using Standard HVAC — Not Pharma HVAC

A generic HVAC contractor cannot design a Schedule M-compliant system. Incorrect zoning, wrong pressure differentials, or missing HEPA qualifications are leading causes of CDSCO inspection failures in newly built Indian facilities.

No Scalability Planning

Designing only for today's output means another expensive re-qualification in 3–5 years. Proper facility engineering allocates space for future lines, additional utility capacity, and modular cleanroom expansion — at zero extra cost upfront.

Treating Documentation as an Afterthought

Many manufacturers complete construction and then scramble to create DQ and qualification documents. Regulators expect design documents to precede construction — not be written post-facto. This is a data integrity red flag under revised Schedule M.

Wrong Airflow Patterns in Cleanrooms

Failing to model airflow patterns before construction leads to turbulence, dead zones, and particle accumulation — especially at Grade A/B boundaries. CFD (Computational Fluid Dynamics) airflow modelling prevents this before a single brick is laid.

Ignoring Material Transfer & Airlock Design

Airlocks and material transfer hatches must be sized correctly for your actual material volumes and interlocked to prevent simultaneous opening. Insufficient airlock design is one of the most commonly cited Schedule M deviations in CDSCO audits.

Utility Systems Not Designed for Validation

Purified Water and WFI loops with dead legs, inaccessible sampling points, or unvalidated sanitisation procedures fail qualification. Utilities must be designed for validation from the start — not modified during IQ to add sampling ports.

Why Choose Us

Why Leading Pharma Companies Choose traccglobal for Facility Engineering

We are not just engineers. We understand regulatory inspections from the inside — and we design facilities that impress inspectors, not just architects.

Regulatory-First Design Philosophy

Every design decision is made with the regulatory submission in mind. We think like CDSCO and US FDA inspectors, so you are never surprised during audit.

Deep India Expertise + Global Reach

We understand CDSCO Schedule M, State Drug Controller processes, and Indian construction realities — combined with direct experience in US FDA, EU GMP, and WHO-GMP compliance.

End-to-End Project Ownership

From first scoping call to final regulatory approval — one team, one point of accountability. No handoff gaps between design and validation. No documentation silos.

BIM-Based Precision Engineering

Our BIM and 3D modelling approach eliminates costly on-site design changes, reduces construction delays, and creates an accurate digital twin for future modifications.

Multi-Product & Multi-Site Experience

Oral solids, sterile injectables, biologics, APIs, medical devices — we have engineered them all, across single-product greenfield builds and complex multi-product retrofit projects.

Transparent Project Management

Real-time project dashboards, structured stage-gate reviews, and milestone-based billing. You always know exactly where your project stands and what comes next.

Frequently Asked Questions

Facility Design & Engineering — Your Questions Answered

These are the most common questions we receive from pharma and biotech companies in India and globally. Answers are structured for quick, clear reading.

What is pharmaceutical facility design and why does it matter?

Pharmaceutical facility design is the end-to-end process of planning, engineering, and constructing a manufacturing plant that produces medicines safely and in compliance with GMP regulations. It matters because the physical design of your facility directly determines whether your medicines will be contamination-free, whether your regulatory submissions will be approved, and whether your production will be efficient and scalable. Poorly designed facilities are the root cause of most regulatory warning letters, product recalls, and costly compliance remediation programmes.

What does CDSCO Schedule M require for facility design in India?

CDSCO Schedule M (under the Drugs and Cosmetics Rules, 1945) requires that Indian pharmaceutical manufacturing facilities meet the following design standards: (1) Adequate space and separation for all manufacturing, storage, QC, and utility areas; (2) Unidirectional flow of materials, personnel, and waste to prevent cross-contamination; (3) HVAC systems with HEPA filtration for sterile areas, validated air handling, and continuous environmental monitoring; (4) Purified Water and WFI systems meeting pharmacopoeial specifications; (5) GMP-grade construction materials (epoxy floors, coved corners, SS fixtures); and (6) Documented qualification (IQ/OQ/PQ) of all critical systems. The revised Schedule M (2023 notification) additionally requires electronic records compliance, quality risk management, and computerised systems validation for new facilities.

How much does it cost to design and build a pharmaceutical facility in India?

The cost of pharmaceutical facility design and construction in India varies widely by facility type and size. A small OSD (tablet/capsule) greenfield facility typically costs ₹5–15 crore for construction plus engineering. A sterile injectable facility with aseptic filling (Grade A/B cleanrooms) ranges from ₹20–80 crore. A large biologics or biotech facility can exceed ₹200 crore. Engineering design fees typically represent 5–12% of total capital cost. Operating in India offers a significant cost advantage — typically 30–50% lower capital cost compared to equivalent facilities in Europe or the US, while meeting the same WHO-GMP and US FDA standards.

What is the difference between ISO Grade A, B, C, D cleanrooms in pharma?

The EU GMP and CDSCO cleanroom classification system uses Grades A through D: Grade A (ISO 5) is used for the highest-risk operations — aseptic filling, stopper placement, and any open product exposure. It requires unidirectional (laminar) airflow at 0.45 m/s. Grade B (ISO 7) is the background environment for Grade A operations and is used for sterile gowning. Grade C (ISO 8) is for less critical sterile steps like solution preparation and buffer preparation. Grade D is a controlled (not classified) area used for non-sterile operations like granulation, tablet compression, and blister packaging. Each grade has defined maximum particle counts at 0.5 μm and 5 μm, both at-rest and in-operation, as specified in EU GMP Annex 1 (revised 2022) and CDSCO Schedule M.

How long does pharmaceutical facility design and construction take?

Typical timelines are: Concept design — 2–6 weeks; Basic (FEED) engineering — 6–10 weeks; Detailed engineering — 10–16 weeks; Construction — 6–18 months depending on size and complexity; Commissioning and qualification — 8–16 weeks; Regulatory approval (CDSCO Drug Manufacturing Licence) — 2–6 months after submission. Total for a greenfield facility: 18–30 months. Facility upgrades and expansions are typically 6–14 months. Modular cleanroom installations for biotech startups can be completed in 4–6 months.

Can an Indian pharma facility designed for CDSCO also get US FDA or WHO-GMP approval?

Yes — and this is becoming increasingly common. India is the world’s largest exporter of generic medicines, and hundreds of Indian facilities are approved by both CDSCO and the US FDA or WHO-GMP. The key is designing to the higher standard from the beginning. Revised CDSCO Schedule M now substantially aligns with WHO-GMP and, in many areas, with US FDA 21 CFR Part 211. With the right design approach, a single facility can satisfy Indian domestic licensing requirements while also being fully inspection-ready for US FDA, EU GMP, or WHO-GMP export audits — without costly parallel compliance programmes.

What are the HVAC requirements for a pharmaceutical cleanroom in India?

Under CDSCO Schedule M, pharmaceutical cleanroom HVAC must: use HEPA-filtered air supply (H14 grade for Grade A/B areas); maintain positive pressure differentials of at least 10–15 Pa between adjacent clean zones; control temperature (typically 20–25°C) and relative humidity (40–60%); be validated through IQ/OQ/PQ qualification; and be monitored in real-time with alarms for out-of-specification conditions via a Building Management System (BMS). Air change rates must be validated per product contamination risk — not simply prescribed numbers. HVAC systems account for 50–80% of a facility’s energy consumption, so energy-efficient design using variable air volume (VAV) systems and heat recovery is strongly recommended for new builds.

What documents are needed for a CDSCO Drug Manufacturing Licence application?

A CDSCO Drug Manufacturing Licence (Form 25/28) application requires: Site Master File (SMF) with full facility description; approved plant layout drawings showing room dimensions, HVAC zones, and material/personnel flow; HVAC system design and qualification reports; water system design and test reports; equipment list with make, model, and GMP compliance status; SOPs for key manufacturing operations; and the applicant’s quality management system documentation. State Drug Controller (SDC) requirements may vary slightly by state. Our facility engineering package delivers all these documents in a format aligned with current CDSCO inspection expectations.

Is Your Design History File Truly Audit-Ready?

Tell us about your project — product type, target markets, timeline, and site location — and we’ll provide a detailed scope and fee estimate within 5 working days. No obligation. No generic proposals.